Enveda raises $311M to advance nature-derived AI drugs into clinical trials
Audio narration · Coming soon
Enveda has secured $311 million in funding, valuing the AI biotech company at $2 billion. The company is currently testing drugs focused on treating skin conditions and maintaining weight loss after discontinuing GLP-1 treatments. This funding round aims to accelerate the development of nature-derived AI drugs into clinical trials.
Why this matters
PRISM scored this story 65/100 for interest.
Originally published by gnews